Interviews
The year is off to a good start for the Japanese pharma with back-to-back approvals in the US. CEO Ken Keller talked to Scrip about some recent setbacks and looking ahead.
Continuing to grow Nuplazid and Daybue are top priorities along with pipeline and business development, Catherine Owen Adams told Scrip.
The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.
CEO David Lee, who oversees Servier’s US business, and chief scientific officer Claude Bertrand talked to Scrip at J.P. Morgan about expanding into neurology through business development.
BioMarin chief business officer James Sabry recently joined the company from Roche and talked to Scrip about plans to jumpstart BD at the smaller company.
Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.
XGene's pain candidate has shown positive results in a US bunionectomy trial and the Chinese company is also eyeing chronic and cancer pain indications for its contender, which may provide a competitor to Vertex's suzetrigine.
The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.
The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.
Merck’s India head for process solutions and Aragen Bioscience’s CEO talk about an incubator set-up and AI-led drug discovery to enable India’s research ecosystem, US tariffs on China, ADC and GLP-1 development, funding path for Goldman Sachs-investee Aragen and more in this video interview
Adam Steensberg talked to Scrip about his firm’s vision for obesity treatment, Zealand’s independence from neighbor Novo Nordisk, and the hunt for a partner for its amylin candidate, petrelintide.
Sanofi's EVP, manufacturing and supply, Brendan O’Callaghan, tells Scrip how modular concept manufacturing at a new site in Singapore can drive efficiencies and minimize downtime, with technologies such as digital twins expected to further improve operational metrics.
The immunology company has used business development to bring in atopic dermatitis bispecific antibodies. J&J VP-immunodermatology disease area leader Liza O’Dowd talked to Scrip about the developments.
The Dutch group has assembled an impressive syndicate which is betting that the first-in-class monoclonal antibody CIT-013 could be a transformative treatment for rheumatoid arthritis and hidradenitis suppurativa.
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
While most drug development in the multiple sclerosis space has focused just on relapse prevention, Immunic’s dual-acting therapy vidofludimus calcium also offers a novel approach for neurodegeneration, its CEO Daniel Vitt tells Scrip.